BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33981016)

  • 1. Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
    Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW
    Br J Cancer; 2021 Jul; 125(2):265-276. PubMed ID: 33981016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.
    Currier MA; Stehn JR; Swain A; Chen D; Hook J; Eiffe E; Heaton A; Brown D; Nartker BA; Eaves DW; Kloss N; Treutlein H; Zeng J; Alieva IB; Dugina VB; Hardeman EC; Gunning PW; Cripe TP
    Mol Cancer Ther; 2017 Aug; 16(8):1555-1565. PubMed ID: 28522589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects.
    Wang Y; Stear JH; Swain A; Xu X; Bryce NS; Carnell M; Alieva IB; Dugina VB; Cripe TP; Stehn J; Hardeman EC; Gunning PW
    Mol Cancer Res; 2020 Jul; 18(7):1074-1087. PubMed ID: 32269073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
    Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
    Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular integration of the anti-tropomyosin compound ATM-3507 into the coiled coil overlap region of the cancer-associated Tpm3.1.
    Janco M; Rynkiewicz MJ; Li L; Hook J; Eiffe E; Ghosh A; Böcking T; Lehman WJ; Hardeman EC; Gunning PW
    Sci Rep; 2019 Aug; 9(1):11262. PubMed ID: 31375704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    Dasari VR; Carey DJ; Gogoi R
    BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Agents on Spindle Assembly Checkpoint to Sensitize Vinorelbine-Induced Mitotic Cell Death Against Human Non-Small Cell Lung Cancers.
    Chang YC; Tseng YL; Leu WJ; Du CM; Jiang YH; Hsu LC; Hsu JL; Hou DR; Guh JH
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32764382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
    Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
    Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-128/homeobox B8 axis regulates ovarian cancer cell progression.
    Li R; Gong L; Li P; Wang J; Bi L
    Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):499-507. PubMed ID: 31271703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and epithelial ovarian cancer therapeutics.
    Patel S; Kumar L; Singh N
    Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
    Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
    Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
    Amaya C; Luo S; Baigorri J; Baucells R; Smith ER; Xu XX
    BMC Cancer; 2021 Sep; 21(1):981. PubMed ID: 34470602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.
    He J; Shi XY; Li ZM; Pan XH; Li ZL; Chen Y; Yan SJ; Xiao L
    BMC Mol Cell Biol; 2019 Nov; 20(1):49. PubMed ID: 31718559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
    Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
    Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
    Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
    Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.